The White Ribbon Project

Today we honor Juneteenth, a day of freedom, reflection, and continued commitment to justice.

In lung cancer advocacy, that commitment includes health equity: access to screening, early detection, biomarker testing, treatment, clinical trials, and compassionate care for every person.

Equity matters. Lives depend on it. 🤍✨🫁

Anyone with lungs can get lung cancer, and no one ever deserves it.

This is why biomarker testing matters. 🫁🤍✨

Thank you to Fox2Now Saint Louis, LCFA: Lung Cancer Foundation of America, 11-year lung cancer survivor Fete ByColette, and Dr. Julie Brahmer for helping bring attention to how biomarker testing is changing lung cancer treatment.

For people diagnosed with lung cancer, biomarker testing can help identify specific changes driving the cancer and may open the door to more personalized treatment options, including targeted therapies.

Research is changing and saving lives.�This is why every person diagnosed with lung cancer at any stage deserves access to comprehensive biomarker testing and care guided by the most current science.

Progress in lung cancer is real, but people cannot benefit from advances they do not know about or cannot access.

Awareness, education, access, self-advocacy and research matter.

Anyone with lungs can get lung cancer, and no one ever deserves it.

How biomarker testing is changing lung cancer treatment To learn more, visit LCFAmerica.orgSt. Louis News: FOX 2 covers n...

Agenda update.

Join Zoom Meeting

https://zoom.us/j/95747503292?pwd=yKiCLoz3naplGcYfpXVDQlt9oTZ2Ck.1

Meeting ID: 957 4750 3292

Passcode: 814387

This is the kind of progress that gives our community hope. continue to rise. 🫁🤍✨

Thank you to Fox Chase Cancer Center and Labcorp for collaborating on a clinical trial to evaluate an ultra-sensitive blood-based test for early-stage non-small cell lung cancer recurrence risk.

For people treated with curative intent, the fear of recurrence is very real. Tools that may help detect molecular recurrence earlier, before traditional imaging or symptoms, could be a meaningful step toward more personalized follow-up, better decision-making, and improved outcomes.

This is why research, and early detection matter.
This is why lung cancer must continue to receive the urgency, innovation, and attention it deserves.

We are grateful to see lung cancer research moving forward and hopeful for what this could mean for patients and families.

Anyone with lungs can get lung cancer, and no one ever deserves it.

https://bit.ly/4egR4Td

Fox Chase Cancer Center has launched a new clinical trial collaboration with Labcorp to evaluate a blood test designed to detect signs of lung cancer recurrence earlier than traditional monitoring methods.

Led by Hossein Borghaei, DO, MS, Chief of the Division of Thoracic Medical Oncology at Fox Chase, the study will explore whether measuring circulating tumor DNA in the bloodstream can help identify recurrence risk in patients with early-stage non-small cell lung cancer.

Summer is here, and there is so much hope and momentum to share. ☀️🤍🫁

Please join us for The White Ribbon Project Community Call on Saturday, June 20, 2026, from 12:00–1:00 PM EST.

We are excited to welcome Dr. Nasser Hanna, Maggie McClosky, and Priyanka Senthil, along with updates from The White Ribbon Project Directors and Officers.

We’ll hear key takeaways from ASCO 2026, exciting End Lung Cancer Now updates, a powerful advocacy journey, important screening work, and more.

Patients, survivors, care partners, advocates, clinicians, researchers, and loved ones are welcome.

Join Zoom Meeting:
https://zoom.us/j/95747503292?pwd=yKiCLoz3naplGcYfpXVDQlt9oTZ2Ck.1
Meeting ID: 957 4750 3292
Passcode: 814387

Awareness is growing. Research is moving. Survivorship is expanding. There is so much hope.
We hope you’ll join us.

This is hope, progress, and survivorship moving forward. 🫁🤍✨

We are so grateful to Dr. Kristin Higgins, Chief Clinical Officer and Professor in the Department of Radiation Oncology at City of Hope Atlanta, for bringing lung cancer survivorship issues to the forefront.

As more people with lung cancer are living longer and exceeding life expectancy, we must also recognize the new and evolving needs that come with survivorship.

Long-term survival brings new questions, new challenges, and the need for multidisciplinary care that supports the whole person, not only the cancer.

This is an exciting and hopeful time for people living with lung cancer. Progress in treatment means more people are living longer, and now survivorship care must grow with them.

We are grateful to see these important conversations happening and to see lung cancer survivorship being recognized, studied, and prioritized so patients and people with lung cancer can keep going! 🤍✨🫁

Anyone with lungs can get lung cancer, and no one ever deserves it.

Fifteen years ago, long-term survival in lung cancer was not something oncologists planned around. That is starting to change. Dr. Kristin Higgins, chief clinical officer at @cityofhopeatlanta and radiation oncologist, has watched targeted therapy reshape outcomes for patients with specific genetic mutations in non-small cell lung cancer. The latest long-term data from the CROWN study showed that patients with ALK-mutated disease treated with lorlatinib had not yet reached median progression-free survival. For Dr. Higgins, those results signal something the field has not been able to say before. Lung cancer now has long-term survivors. And for the first time, oncologists can start building survivorship care to match. This special edition of On the Edge of Breakthrough: Voices of Cancer Research is out now. Tune in to hear Dr. Higgins, along with Dr. Alan Bryce and Dr. Joseph Mikhael, on the research shaping conversations at @ascocancer 2026. Link in bio. #ASCO26

This is hope. This is progress. This is why research matters. 🫁🤍

Thank you to WBOC TV 16 for sharing this important story about targeted proton therapy offering new hope for people with lung cancer.

For Marie Francillon and her daughter Rachelle Francillon, this is not just about treatment. It is about more time, more memories, and more moments together.

Every advance matters. More precise treatments can mean more options, fewer complications, better quality of life, and more time with the people we love.

For people diagnosed with lung cancer, hope is not abstract. Hope is science moving forward. Hope is access to better treatments. Hope is knowing that progress is happening every day. Even in late stage diagnosis there is great hope today.

We are grateful to see lung cancer stories being shared, discussed, and brought into the public conversation.

Awareness grows. Research advances. Lives change.

Anyone with lungs can get lung cancer, and no one ever deserves it.

Targeted Proton Therapy Offers Hope For Lung Cancer Patients Experts say proton therapy can offer a more targeted approach than traditional radiation.

Day 4️⃣

Many people don't realize the impact lung cancer has on women.

In fact, more women die from lung cancer each year than breast and ovarian cancers combined. But, lung cancer is often left out of conversations about women's health.

That's why awareness matters. The more women understand their risk, the more empowered they are to advocate for their health.

Share this post to help spread awareness!

This is why we continue to grow awareness and community. It makes us stronger and leads to progress.

Thank you GO2 for Lung Cancer for leading this effort.